LIGAND PHARMACEUTICALS INC (LGND)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 100M 200M 300M Q3 '16: 92M Q4 '16: 109M Q1 '17: 135.5M Q2 '17: 206M Q3 '17: 230M Q4 '17: 251.5M Q1 '18: 251.5M Q2 '18: 251.5M Q3 '18: 251.5M Q4 '18: 251.5M Q1 '19: 238.8M Q2 '19: 173.7M Q3 '19: 152.9M Q4 '19: 120.3M Q1 '20: 110M Q2 '20: 126.4M Q3 '20: 143.4M Q4 '20: 186.4M Q1 '21: 208.4M Q2 '21: 251.7M Q3 '21: 274.6M Q4 '21: 261.1M Q1 '22: 242.4M Q2 '22: 207.9M Q3 '22: 202.3M Q4 '22: 196.2M Q1 '23: 203.7M Q2 '23: 179.9M Q3 '23: 153.6M Q4 '23: 131.3M Q1 '24: 118.3M Q2 '24: 133.5M Q3 '24: 152.4M Q4 '24: 167.1M Q1 '25: 181.5M Q2 '25: 187.6M Q3 '25: 251.2M Q4 '25: 268.1M Q1 '26: 274.5M Q2 '26: 290.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 90M 180M 270M Q4 '17: 246.1M Q1 '18: 245.6M Q2 '18: 245.4M Q3 '18: 246.3M Q4 '18: 245.1M Q1 '19: 229.4M Q2 '19: 163M Q3 '19: 140.5M Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-350M 0 350M 700M 1.1B Q3 '15: 25.9M Q4 '15: 27.3M Q1 '16: 39.1M Q2 '16: 38.7M Q3 '16: 35.5M Q4 '16: 43.9M Q1 '17: 39M Q2 '17: 48.1M Q3 '17: 59.1M Q4 '17: 68.1M Q1 '18: 94.9M Q2 '18: 152.1M Q3 '18: 158.9M Q4 '18: 163.7M Q1 '19: 953.2M Q2 '19: 878.9M Q3 '19: 850.4M Q4 '19: 807.1M Q1 '20: -15.7M Q2 '20: -4.4M Q3 '20: 4.5M Q4 '20: 37.5M Q1 '21: 38.4M Q2 '21: 77.1M Q3 '21: 89M Q4 '21: 103.8M Q1 '22: 101.3M Q2 '22: 64.2M Q3 '22: 60.8M Q4 '23: 11.9M Q1 '24: 725K Q2 '24: -16.4M Q3 '24: -16.3M Q4 '24: -22.6M Q1 '25: -61.8M Q2 '25: -34.3M Q3 '25: 17.5M Q4 '25: 41M Q1 '26: 94.6M Q2 '26: 94.7M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-300M 0 300M 600M 900M Q3 '16: 7.8M Q4 '16: -1.6M Q1 '17: -3.2M Q2 '17: 9.1M Q3 '17: 16.4M Q4 '17: -22.9M Q1 '18: 17.3M Q2 '18: 84.4M Q3 '18: 143.3M Q4 '18: 143.3M Q1 '19: 764.4M Q2 '19: 676.8M Q3 '19: 594.2M Q4 '19: 629.3M Q1 '20: -61.2M Q2 '20: -24.7M Q3 '20: -16.1M Q4 '20: -3M Q1 '21: 39.3M Q2 '21: 47.9M Q3 '21: 68.3M Q4 '21: 57.1M Q1 '22: 23.6M Q2 '22: -8M Q3 '22: -21.3M Q4 '22: -33.4M Q1 '23: 24M Q2 '23: 27.2M Q3 '23: 16.5M Q4 '23: 52.2M Q1 '24: 96.3M Q2 '24: 42.1M Q3 '24: 45.2M Q4 '24: -4M Q1 '25: -132.6M Q2 '25: -75.9M Q3 '25: 48.6M Q4 '25: 124.5M Q1 '26: 153.6M Q2 '26: 197.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 5M 10M 15M Q4 '17: 5.4M Q1 '18: 5.8M Q2 '18: 6M Q3 '18: 5.1M Q4 '18: 6.3M Q1 '19: 9.4M Q2 '19: 10.7M Q3 '19: 12.4M Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19

Operating Cash Flow TTM

-70M 0 70M 140M 210M Q3 '16: 55.7M Q4 '16: 60.7M Q1 '17: 66.8M Q2 '17: 66.9M Q3 '17: 76M Q4 '17: 88.6M Q1 '18: 130.1M Q2 '18: 193.4M Q3 '18: 192.8M Q4 '18: 194.1M Q1 '19: 178.6M Q2 '19: 43.9M Q3 '19: 10.6M Q4 '19: -29.3M Q1 '20: -57.7M Q2 '20: 27.8M Q3 '20: 46.7M Q4 '20: 54.6M Q1 '21: 48.4M Q2 '21: 44.4M Q3 '21: 51.7M Q4 '21: 78.8M Q1 '22: 120.1M Q2 '22: 111.6M Q3 '22: 112M Q4 '22: 137.8M Q1 '23: 119.8M Q2 '23: 107.8M Q3 '23: 95M Q4 '23: 49.6M Q1 '24: 34.4M Q2 '24: 47.8M Q3 '24: 76.6M Q4 '24: 97M Q1 '25: 52.9M Q2 '25: 55.4M Q3 '25: 31.9M Q4 '25: 49.4M Q1 '26: 123.5M Q2 '26: 131.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-50M 0 50M 100M 150M Q2 '11: -16.1M Q3 '11: -9.6M Q4 '13: 20.3M Q1 '14: 20.8M Q2 '14: 18M Q3 '14: 22.2M Q4 '14: 20.6M Q1 '15: 25.6M Q2 '15: 31.6M Q3 '15: 38.3M Q4 '15: 41.6M Q1 '16: 46.9M Q2 '16: 46.5M Q3 '16: 53.8M Q4 '16: 58.9M Q1 '17: 65.1M Q2 '17: 65.8M Q3 '17: 75.7M Q4 '17: 86.4M Q2 '21: 36M Q3 '21: 43.5M Q4 '21: 70M Q1 '22: 109.8M Q2 '22: 96.1M Q3 '22: 94M Q4 '22: 119.9M Q1 '23: 104.3M Q2 '23: 98.8M Q3 '23: 89.7M Q4 '23: 46.1M Q1 '24: 33.1M Q2 '24: 46.3M Q3 '24: 75.1M Q4 '24: 95.2M Q1 '25: 50.9M Q2 '25: 53.6M Q3 '25: 30.8M Q4 '25: 48.9M Q1 '26: 123M Q2 '26: 131.4M Q2 '14 Q3 '15 Q4 '16 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 9M 18M 27M Q4 '15: 21.5M Q1 '16: 22.3M Q2 '16: 20.8M Q3 '16: 23M Q4 '16: 20.9M Q1 '17: 23M Q2 '17: 23.2M Q3 '17: 23.6M Q4 '17: 21.1M Q1 '18: 24.8M Q2 '18: 24.4M Q3 '18: 24.1M Q4 '18: 21.1M Q1 '19: 21.3M Q2 '19: 19.6M Q3 '19: 18.8M Q4 '19: 17.2M Q1 '20: 16.5M Q2 '20: 16.7M Q3 '20: 16.1M Q4 '20: 16.7M Q1 '21: 17.2M Q2 '21: 17.2M Q3 '21: 17.1M Q4 '21: 16.7M Q1 '22: 16.8M Q2 '22: 17.1M Q3 '22: 17.1M Q4 '22: 16.9M Q1 '23: 18M Q2 '23: 17.7M Q3 '23: 17.4M Q1 '24: 18.1M Q2 '24: 18M Q3 '24: 18.4M Q1 '25: 19.2M Q2 '25: 19.9M Q3 '25: 20.6M Q1 '26: 19.9M Q2 '26: 21.8M Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 0.00 15.00 30.00 45.00 Q3 '15: 10.77 Q4 '15: 10.72 Q1 '16: 10.98 Q2 '16: 9.57 Q3 '16: 0.34 Q4 '16: 0.20 Q1 '17: 0.12 Q2 '17: 0.68 Q3 '17: 0.99 Q4 '17: -1.18 Q1 '18: 0.43 Q2 '18: 3.16 Q3 '18: 5.60 Q4 '18: 5.60 Q1 '19: 35.09 Q2 '19: 31.36 Q3 '19: 27.75 Q4 '19: 29.34 Q1 '20: -3.44 Q2 '20: -1.38 Q3 '20: -0.99 Q4 '20: -0.21 Q1 '21: 2.30 Q2 '21: 2.77 Q3 '21: 3.99 Q4 '22: -1.99 Q1 '23: 1.25 Q2 '23: 1.43 Q3 '23: 0.82 Q4 '23: 2.90 Q1 '24: 5.32 Q2 '24: 2.31 Q3 '24: 2.51 Q4 '24: -0.22 Q1 '25: -7.18 Q2 '25: -4.06 Q3 '25: 2.01 Q4 '25: 5.89 Q1 '26: 7.43 Q2 '26: 9.41 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.